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Abstract We previously reported that endostatin inhibits
endothelial and tumor cellular invasion by blocking activation
and catalytic activity of matrix metalloproteinase (MMP)-2.
Here we have examined the domain of proMMP-2 responsible
for the binding of endostatin using surface plasmon resonance.
ProMMP-2 and proMMP-2vHP lacking the hinge and
hemopexin-like (HP) domains bound little to the immobilized
endostatin. The active MMP-2 and MMP-2vHP, but not the
HP domain of MMP-2, bound to endostatin at similar levels. In
addition, preincubation of MMP-2 and MMP-2vHP with the
MMP inhibitor actinonin, which binds to the active site of
MMP-2, abolished their bindings to endostatin. These results
indicate that endostatin binds to neither the latent proMMP-2
nor the HP domain but to the catalytic domain of MMP-
2. & 2002 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Endostatin, the 20-kDa C-terminal proteolytic fragment of
collagen XVIII, was ¢rst identi¢ed in the conditioned media
of hemangioendothelioma cells as an anti-angiogenic molecule
[1]. Administration of the recombinant endostatin or endo-
statin gene therapy has been shown to suppress tumor growth
and angiogenesis in mice of various tumor models [2,3]. On
the cellular level, it was reported that endostatin inhibits en-
dothelial cell proliferation [1] and migration [4,5] and induces
endothelial cell apoptosis [6] and cell cycle arrest [7]. However,
molecular targets and action mechanisms of endostatin have
not been clearly elucidated.
Matrix metalloproteinases (MMPs), a family of zinc-depen-
dent endopeptidases, are involved in angiogenesis and tumor
metastasis [8]. MMP-2 can degrade various components of the
extracellular matrix including type IV collagen, a major com-
ponent of basement membranes. Like other MMPs except
membrane types, MMP-2 is produced in a latent form
(proMMP-2) requiring activation. The catalytic activity of
MMP-2 is largely inhibited by tissue inhibitor of metallopro-
teinase (TIMP)-2 that binds to the active MMP-2 as well as
proMMP-2 at 1:1 stoichiometric ratio [9], although TIMP-2
at a low concentration enhances activation of proMMP-2 at
the cell surface [10]. It has been recently shown that tumor
progression and angiogenesis were reduced in MMP-2-de¢-
cient mice [11] and that MMP-2 was required for the switch
to the angiogenic phenotype in a tumor model [12].
We previously reported that endostatin inhibits endothelial
and tumor cellular invasion by blocking the activation and
catalytic activity of MMP-2 [13]. Here we have determined
which domain of proMMP-2 interacts with endostatin by sur-
face plasmon resonance (SPR) analysis.
2. Materials and methods
2.1. Preparation of the recombinant mouse endostatin and
human TIMP-2
The recombinant mouse endostatin corresponding to the C-terminal
184 amino acids of mouse collagen XVIII was expressed in HEK293
cells and puri¢ed with heparin-Sepharose CL-6B column (Amersham
Biosciences) and Superdex 75 column (Amersham Biosciences) chro-
matography as described previously [13]. The puri¢ed endostatin was
dialyzed in phosphate-bu¡ered saline (PBS) and stored at 370‡C.
The recombinant human TIMP-2 was expressed in Sf9 cells with
infection of the TIMP-2 baculovirus [14]. Puri¢cation of the recombi-
nant TIMP-2 was followed by a method described [15].
2.2. Preparation of proMMP-2, proMMP-2vHP, GST-fused MMP-2
HP domain, and GST
The recombinant human proMMP-2 was expressed in Sf9 cells with
infection of the 72Gel baculovirus and puri¢ed with gelatin^agarose
column chromatography as described previously [16]. The human
proMMP-2 lacking the hinge and hemopexin-like (HP) domains
(proMMP-2vHP), which was processed in the medium of the Sf9 cells
infected with the 72Gel baculovirus, was enriched by gelatin^agarose
column chromatography. To purify proMMP-2vHP, the eluted pro-
teins were subjected to gel ¢ltration chromatography using a Superdex
75 column equilibrated with an MMP assay bu¡er (20 mM Tris^HCl,
pH 7.5, 150 mM NaCl, 5 mM CaCl2, 100 WM ZnCl2, and 0.025% Brij
35). pGEX-4T-1-MMP2-HP was constructed by the introduction of a
cDNA fragment encoding the MMP-2 HP domain (Cys469^Cys660)
into EcoRI^XhoI sites of pGEX-4T-1. The GST-fused MMP-2 HP
domain and GST were expressed in E. coli containing pGEX-4T-1-
MMP-2-HP and pGEX-4T-1, respectively, and puri¢ed by Gluta-
thione-Sepharose 4B (Amersham Biosciences) column chromatogra-
phy following the manufacturer’s manual.
2.3. SDS^PAGE and gelatin zymography
Proteins were separated by SDS^PAGE and visualized by staining
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with Coomassie brilliant blue R-250. Gelatin zymography was per-
formed in 10% SDS^PAGE containing 0.1% gelatin as described
[16].
2.4. Catalytic activity of MMP-2 and MMP-2vHP
The puri¢ed proMMP-2 and proMMP-2vHP were activated in the
presence of a ¢nal concentration of 1 mM 4-aminophenylmercuric
acetate (APMA) at 37‡C for 30 min. The APMA-activated enzymes
(10 nM) were incubated in 50 Wl of the MMP assay bu¡er containing
1 WM of a quenched £uorescent peptide, Mca-Pro-Leu-Gly-Leu-
Dap(Dnp)-Ala-Arg-NH2 (M1895, Bachem), as a substrate at 37‡C
for 30 min [17]. The reaction was stopped by the addition of 0.1 M
sodium acetate (pH 4.0) at ¢nal concentration. The £uorescence was
measured at excitation wavelength 328 nm and emission 393 nm.
2.5. SPR analysis using BIAcore
Bindings between endostatin or TIMP-2 and various MMP-2 spe-
cies were analyzed by SPR technology using BIACORE 3000 (BIA-
core) as described [18] with a minor modi¢cation. A sensor chip CM5,
which consists of carboxymethylated dextran on a gold thin layer, was
used for all experiments. The surface was activated by injecting a
mixture of 0.2 M N-ethyl-NP-dimethylaminopropyl-carbodiimide
and 0.05 M N-hydroxysuccinimide. After activation, endostatin or
TIMP-2 in a coupling bu¡er (10 mM sodium acetate, pH 5.0) was
injected for immobilization to the chip surface. The activated surface
that was not immobilized with a ligand was blocked by 1 M ethanol-
amine^HCl (pH 8.5). PBS and the MMP assay bu¡er were used as
running bu¡ers during immobilization and binding analysis, respec-
tively. In typical experiments, each immobilization level of endostatin
and TIMP-2 was about 2200 response units (RU).
One hundred nM of analyte (latent or active MMP-2, latent or
active MMP-2vHP, GST-fused MMP-2 HP domain, or GST) was
injected to pass through the unmodi¢ed reference £ow cell, the £ow
cell immobilized with endostatin, and then the £ow cell immobilized
with TIMP-2, for 2 min at a £ow rate of 5 Wl/min. For regeneration,
proteins bound to ligands were removed by 1-min pulse injections of
3.3 mM NaOH and 133 mM NaCl for the endostatin £ow cell and 20
mM HCl for the TIMP-2 £ow cell. These regeneration conditions
allowed for the retention of greater than 95% of the original capacity
for binding to the active MMP-2. To correct for bulk shift, data in the
reference £ow cells were subtracted from experimental data.
3. Results and discussion
3.1. Preparation and characterization of the human proMMP-2
and its domains
In an attempt to determine which domain of MMP-2 inter-
Fig. 1. Characterization of the puri¢ed proMMP-2, proMMP-2vHP, and GST-fused MMP-2 HP domain. ProMMP-2, proMMP-2vHP, and
GST-fused MMP-2 HP domain (GST-MMP-2 HP) are schematically represented (A). The puri¢ed proMMP-2, proMMP-2vHP, GST-fused
MMP-2 HP domain, and GST were analyzed by 10% SDS^PAGE under reducing condition (B). The puri¢ed proMMP-2 and proMMP-2vHP
without (3) or with (+) APMA activation were analyzed in gelatin zymography (C). Catalytic activities of the puri¢ed proMMP-2 (black bar)
and proMMP-2vHP (white bar) without (3) or with (+) APMA were measured by £uorogenic peptide cleavage assay (D). The catalytic activ-
ity of each enzyme (10 nM) was expressed as a relative activity to that of the active MMP-2. Each value is the meanT standard deviation of
three independent determinations of duplicate experiments.
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acts with endostatin, we have puri¢ed the human proMMP-2,
proMMP-2vHP, GST-fused HP domain, and GST (Fig. 1A).
The 68-kDa proMMP-2 was puri¢ed from the supernatant of
the Sf9 insect cells infected with the 72Gel baculovirus (Fig.
1B). A 48-kDa product of proMMP-2 generated during ex-
pression of proMMP-2 in the Sf9 cells [16] was puri¢ed (Fig.
1B). The N-terminal sequence of the 48-kDa product was the
same as that of proMMP-2 (Ala-Pro-Ser-Pro-IleT). The mo-
lecular mass of the 48-kDa product which was determined
using MALDI-TOF mass spectrometry was m/z 47,163 Da
[M+Hþ]. From these mass and N-terminal sequencing data,
the 48-kDa product was expected to be the Ala30^Asp450 of
proMMP-2. Since this region contains the pro- and catalytic
domains of proMMP-2, it was named proMMP-2vHP. The
47-kDa GST-fused MMP-2 HP domain (Cys469^Cys660) and
the 26-kDa GST were expressed as soluble proteins in E. coli
and puri¢ed (Fig. 1B).
Upon APMA activation, the 48-kDa proMMP-2vHP was
converted to the 42-kDa gelatinolytic form, analogous to con-
version of the 68-kDa proMMP-2 to the 62-kDa active MMP-
2 (Fig. 1C). As expected from the presence of pro-domain, the
catalytic activities of both proMMP-2 and proMMP-2vHP,
without APMA activation, were at background levels in £uo-
rogenic peptide cleavage assay (Fig. 1D). In addition, the
catalytic activity of the APMA-activated proMMP-2vHP
was comparable to that of the APMA-activated proMMP-2,
that is, the active MMP-2. These results imply that the 42-
kDa gelatinolytic form processed from proMMP-2vHP is the
active MMP-2vHP.
3.2. Interaction of endostatin with the latent proMMP-2 and
proMMP-2vHP
It has been shown that proMMP-2 binds to TIMP-2 with
high a⁄nity through electrostatic interactions between the HP
domain of MMP-2 and the C-terminal domain of TIMP-2
[19]. In addition, a truncated form of proMMP-2 lacking
the C-terminal domain (Ala447^Cys660), similar to our
proMMP-2vHP, was found to bind poorly to TIMP-2 [20].
To examine whether endostatin interacts with proMMP-2 or
proMMP-2vHP, these proteins were allowed to bind to the
immobilized endostatin and examined by SPR. In addition,
these proMMP-2 species were also applied to the immobilized
TIMP-2 as a control. As shown in Fig. 2B, D, show that the
binding of proMMP-2 to TIMP-2 was strong (2,000 RU at
the end of the association phase) but the binding of proMMP-
2vHP to TIMP-2 was very weak (50 RU). In the same con-
dition, bindings of both proMMP-2 and proMMP-2vHP to
endostatin were barely detectable (only 15 RU and 10 RU,
respectively; Fig. 2A, C). These results indicate that only a
trace amount of the proMMP-2 species, regardless of the
presence of the HP domain, binds to endostatin.
Fig. 2. Interaction between endostatin and either proMMP-2 or proMMP-2vHP. Sensorgrams of proMMP-2 (A, B) and proMMP-2vHP (C,
D) binding to the immobilized endostatin or TIMP-2 as a control were shown. The enzymes (100 nM) were allowed to bind endostatin (A, C)
or TIMP-2 (B, D) and their bindings were examined by SPR analysis as described in Sec. 2. Each enzyme was run in duplicate, the data were
corrected for bulk shift, and the average of the duplicate experiments was plotted. The arrowhead indicates the end of the association phase.
L, ligand; A, analyte.
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3.3. Interaction of endostatin with active MMP-2, active
MMP-2vHP, and the HP domain of MMP-2
To examine which domain of MMP-2 is responsible for
binding to endostatin, the active MMP-2, the active MMP-
2vHP (catalytic domain), and the GST-fused MMP-2 HP
domain were allowed to bind to the immobilized endostatin
and examined by SPR. TIMP-2, which is known to bind to
the catalytic and HP domains with low and high a⁄nities,
respectively [19,21], was used as a positive control. As ex-
pected, the active MMP-2 as well as the GST-fused MMP-2
HP domain bound strongly to TIMP-2 (Fig. 3A, C), but this
binding was signi¢cantly reduced by the deletion of its HP
domain (active MMP-2vHP) (Fig. 3B). Unlike the latent
forms of MMP-2, the active MMP-2 apparently bound to
endostatin although its binding was much weaker compared
to TIMP-2 (Fig. 3A). The active MMP-2vHP also bound to
endostatin (Fig. 3B). The RU for the active MMP-2 at the
end of the association phase (215 RU) was slightly higher
than that for the active MMP-2vHP (175 RU). Considering
that the active MMP-2 and the active MMP-2vHP are 62
kDa and 42 kDa, respectively, their binding a⁄nities to endo-
statin are likely to be similar. Moreover, neither the GST-
fused MMP-2 HP domain (Fig. 3C) nor GST (data not
shown) bound to endostatin. These results indicate that endo-
statin binds to the catalytic domain of MMP-2 but not to the
HP domain of MMP-2. Unfortunately, we could not deter-
mine the dissociation equilibrium constant for the interaction
of endostatin with the active MMP-2 species in SPR analysis,
mainly due to rapid autodegradation of MMP-2 species at
higher concentrations.
3.4. E¡ect of a hydroxamate peptide analog inhibitor of MMPs
in interaction between Endostatin and MMP-2
To examine whether the interaction between endostatin and
the catalytic domain of MMP-2 occurs at the active site of
MMP-2, the active MMP-2 and MMP-2vHP preincubated
with a natural hydroxamate^pseudopeptide MMP inhibitor,
actinonin, were tested for their interaction with endostatin.
Actinonin is known to bind to the active site of MMPs by
the hydroxamate group chelating the catalytic zinc ion and
pseudopeptide side chains interacting with substrate-binding
subsites [22]. As shown in Fig. 4A, B, preincubation of the
active MMP-2 and MMP-2vHP with actinonin completely
prevented their binding to endostatin. However, the binding
of the active MMP-2 to TIMP-2 was slightly decreased by
preincubation of actinonin (Fig. 4C). The binding of the ac-
tive MMP-2vHP to TIMP-2 was also partially reduced by
actinonin (Fig. 4D). Although a complex structure of
MMP-2 and TIMP-2 has not been reported, it is known
that TIMP-2 interacts with the catalytic domain of MMP-14
through six separate segments, including interaction of the
N-terminal ¢ve TIMP-2 residues with the P1^P4P subsites of
the MMP-14 active site [23]. Thus, only a partial decrease of
the interaction of the MMP-2vHP and TIMP-2 in the pres-
ence of actinonin re£ects that TIMP-2 is still able to interact
with the actinonin-bound MMP-2vHP at sites other than the
occupied active site. However, since actinonin completely
blocked the interactions of endostatin with the active MMP-
2 species (Fig. 4A, B), it is most likely that endostatin binds to
the active site of MMP-2.
In a previous study, we showed that endostatin was co-
precipitated with proMMP-2 in a mixture of these proteins
[13]. Therefore, it seems that binding of a trace amount of
proMMP-2 to endostatin in SPR analysis would not be an
artifact. It was reported that the puri¢ed proMMP-2 at a
higher concentration is autoactivated in the absence of exter-
nal activators [24]. This ¢nding suggests that the ‘active’
proMMP-2 in which the pro-domain is dissociated from the
active site should be present at least in a trace amount in a
proMMP-2 population. In addition, we show here that the
catalytic domain of MMP-2 binds to endostatin and that
the unoccupied active site of MMP-2 is required for endo-
statin binding. It is thus likely that proMMP-2 complexed
with endostatin that was detected by sensitive immunoprecip-
itation/Western blot analyses and SPR analysis would be the
Fig. 3. Interaction of endostatin with the active MMP-2, the active
MMP-2vHP, and the GST-fused MMP-2 HP domain. Sensorgrams
of the active MMP-2 (A), the active MMP-2vHP (B), and the GST-
fused MMP-2 HP domain (C) binding to the immobilized endosta-
tin (thick line) or TIMP-2 as a control (thin line) were shown. Ex-
perimental procedures are described in Fig. 2.
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active proMMP-2 present in a trace amount. We therefore
believe that the latent proMMP-2 does not bind to endostatin.
Here we have shown that endostatin binds only to the cat-
alytic domain of MMP-2, while TIMP-2 binds to MMP-2
through interactions with its HP domain at high a⁄nity and
with its catalytic domain at low a⁄nity. Although the inter-
action of the MMP-2 catalytic domain with endostatin was
somewhat weaker than that with TIMP-2, it seems possible
that endostatin inhibits MMPs in the stromal area surround-
ing tumors in which the concentration of MMPs overwhelms
that of TIMPs. Therefore, our ¢ndings suggest that the potent
anti-angiogenic and anti-tumor activities of endostatin are at
least in part associated with its ability to inhibit the activities
of MMP-2 and other MMPs through direct interaction with
their catalytic domains.
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